U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary 0 1 A

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	ÂA	3,674,836	7/4/72	Creger			
0	AB	3,983,140	9/28/76	Endo et al.			
	AC	4,027,009	5/31/77	Grier et al.			
	AD	4,231,938	11/4/80	Monaghan et al.			
4	AE-	4,346,227	8/24/82	Terahara et al.			
	AF	4,448,784	5/15/84	Glamkowski et al.			
·	AG	4,450,171	5/22/84	Hoffman et al.			·
0	AH	4,499,289	2/12/85	Baran et al.			
./	Aì	4,512,988	4/23/85	Weller, III et al.			
1	AJ	4,613,610	9/23/86	Wareing			
-	AK	4,647,576	3/3/87	Hoefle et al.	_		
	AL	4,681,893	7/21/87	Roth			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
7.	AM	EP 0 107 095	9/9/87	EP				
	AN	EP 0 142 146	8/31/88	EP .				
	AO	EP 0 160 546	11/6/85	EP		>		
· ·	AP_	LEP 0 221 025	5/6/87	EP			-0	
	AQ	EP 0 416 740	3/13/91	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<u></u>	AR	Albright, J.D. et al., "Synthesis of 1,4,5,6-Tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine", J. Heterocyclic Chem., Vol. 37, pp. 41-46 (2000)
	AS	Aranyos, A. et al., "Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers", J. Am. Chem. Soc., Vol. 121, No. 18, pp. 4369-4378 (1999)
1	AT_	Arbeeny, C. et al., "The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies", –Curr. Med. Chem Imm., Endoc. & Metab Agents., Vol. 1, No. 1, pp. 1-24 (2001)
EXAMIN	ER	DATE CONSIDERED 11/10/05

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

AMINER VITIAL		DOCUMENT NUMBER	DATE	NAME	CU	ASS SUBC	LASS	FILING DATE
7	2AA	4,686,237	8/11/87	Anderson		-		-
\sim	2AB	4,692,522	9/8/87	Parsons et al.			=	
~	2AC	4,755,509	7/5/88	Teulon				
~-	2AD	4,871,721	10/3/89	Biller				->
\sim	2AE	4,924,024	5/8/90	Biller				
	2AF	5,006,530	4/9/91	Angerbauer et al.				
	2AG	5,011,930	4/30/91	Fujikawa et al.				
_	2AH	5,177,080	1/5/93	Angerbauer et al.				
"/	ŽAI	5,206,235	4/27/93	Fisher et al.				
7	2AJ	5,260,440	11/9/93	Hirai et al.				
	2AK	5,273,995	12/28/93	Roth				
	2AL	5,354,772	10/11/94	Kathawala				
			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	NSLATIC NC
	2AM	EP 0 978 279	2/9/00	EP				
\sim	2AN	EP 1 088 824	1/7/04	EP .				
-	2A0	2 596 393	10/2/87	FR				
	2AP	JP 2000-256318	9/19/00	JP .			0	
-	2AQ	GB 2 205 837	12/21/88	UK .			-0	
		OTHER DOC	UMENTS (Including Author, Title, Date, Pertinen	t pages, E	itc.)		
4	2AR			ient Asymmetric Synthesis of (R n Letters, Vol. 35, No. 20, pp. 32			rahydr	o-1H-
	2AS			rrolidides as Potent, Stable Inhib Letters, Vol. 6, No. 10, pp. 1163			ptidas	e IV",

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

			U.S. I	PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLJ	ASS SUBCL	A\$S	FILING DATE		
c-	3AA	5,385,929	1/31/95	Bjorge et al.						
Ī/	3AB	5,488,064	1/30/96	Sher						
V	3AC	5,491,134	2/13/96	Sher et al.						
/ -	3AD	5,506,219	4/9/96	Robl						
	3AE	5,541,204	7/30/96	Sher et al.						
1	3AF	5,545,735	8/13/96	Bochis et al.						
//~	3AG	5,552,397	9/3/96	Karanewsky et al.						
	3AH	5,594,006	1/14/97	Sakamoto et al.		-				
	3AI	5,595,872	1/21/97	Wetterau, II et al.	•					
1/	3AJ	5,612,359	3/18/97	Murugesan						
1/	3AK	5,614,492	3/25/97	Habener						
7	3AL	5,652,363	7/29/97	Khanna et al.						
			FOREIG	N PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAI YES	NSLATION NO		
	3AM	WO 86/03488	6/19/86	PCT	ν,		<u></u>			
~_	3AN	WO 86/07054	12/4/86	PCT	•=					
	⁷ 3AO	WO 93/14067	7/22/93	PCT						
	3AP	WO 96/36596	11/21/96	PCT						
	3AQ	WO 96/38144	12/5/96	PCT						
,		OTHER DOC	UMENTS (Including Author, Title, Date, Pertinen	t pages, E	itc.)				
6	3AR	benzazepine Derivatives	: X-Ray Crys	rmational Analyses of Some 3-Aminostal Structure of 3S-3-[[(1,1-Dimethyl	ethoxy)ca	rbonyl]amino]				
6	3A\$			in Glucose Levels in STZ Diabeting Approach for Targeting the Liv						
	T									

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

			U.S. F	PATENT DOCUMENTS .					
MINER ITAL		DOCUMENT NUMBER	DATE	NAME	CLA	ss	SUBCLA	ess	FILING DATE
	4AA	5,686,104	11/11/97	Mills et al.			 .		
1	4AB	5,691,322	11/25/97	Robl	_				->
	4AC	5,712,279	1/27/98	Biller et al.				-	
)	4AD	5,712,396	1/27/98	Magnin et al.				-	
1	4AE	5,719,278	2/17/98	Albright et al.	_				
1	4AF	5,739,135	4/14/98	Biller et al.					
	4AG	5,753,675	5/19/98	Wattanasin					
	4AH	5,760,246	6/2/98	Biller et al.					
	4AI	5,770,615	6/23/98	Cheng et al.					
1	4AJ	5,776,983	7/7/98	Washburn et al.					
$\overline{}$	4AK	5,789,587	8/4/98	Fisher et al.					
$\overline{\ }$	4AL	5,827,875	10/27/98	Dickson, Jr. et al.	-				
			FOREIG	N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	OFFICE	22.400	CURC	LASS	TRAI	VSLATI
	†	DOCUMENT NUMBER		OTTICE	CLASS	3080	LASS	YES	N
	4AM	WO 96/39384	12/12/96	PCT .	CLASS	3080		YES	N .
	4AM 4AN				CLASS	3080		YES	
	 	WO 96/39384	12/12/96	PCT .	CLASS	3080		YES	
	4AN	WO 96/39384 WO 96/39385	12/12/96 12/12/96	PCT .	CLASS	3080	LASS	YES	
	4AN 4AO	WO 96/39384 WO 96/39385 WO 97/12613	12/12/96 12/12/96 4/10/97	PCT . PCT	CLASS	3080	LASS	YES	
	4AN 4AO 4AP	WO 96/39384 WO 96/39385 WO 97/12613 WO 97/12615 WO 97/21993	12/12/96 12/12/96 4/10/97 4/10/97 6/19/97	PCT PCT PCT				YES	
	4AN 4AO 4AP	WO 96/39384 WO 96/39385 WO 97/12613 WO 97/12615 WO 97/21993 OTHER DOC	12/12/96 12/12/96 4/10/97 4/10/97 6/19/97 UMENTS (PCT PCT PCT PCT	nt pages, E	Etc.)	and Py	YES	ine
	4AN 4AO 4AP 4AQ	WO 96/39384 WO 96/39385 WO 97/12613 WO 97/12615 WO 97/21993 OTHER DOC Berg-Nielsen, K. et al. Synthesis from a Divir Biller, S.A. et al., "Isop Journal of Medicinal Co	12/12/96 12/12/96 4/10/97 4/10/97 6/19/97 UMENTS (, "Amino-Clanyl Ketone", orenoid (Phothemistry, Vi	PCT PCT PCT PCT Including Author, Title, Date, Pertineral Acta Chemica Scandinavica B, esphinylmethyl)phosphonates as ol. 31, No. 10, pp. 1869-1871 (1	nt pages, E ropargyla Vol. 32, p Inhibitor 988)	mines op. 553	and Py 3-556 (1	YES	ine
	4AN 4AO 4AP 4AQ 4AR	WO 96/39384 WO 96/39385 WO 97/12613 WO 97/12615 WO 97/21993 OTHER DOC Berg-Nielsen, K. et al. Synthesis from a Divir Biller, S.A. et al., "Isop Journal of Medicinal Co	12/12/96 12/12/96 4/10/97 4/10/97 6/19/97 UMENTS (, "Amino-Clanyl Ketone", orenoid (Phothemistry, Vi	PCT PCT PCT PCT Including Author, Title, Date, Pertineraisen Rearrangement of Vinyl Practa Chemica Scandinavica B, esphinylmethyl)phosphonates as	nt pages, E ropargyla Vol. 32, p Inhibitor 988)	mines op. 553	and Py 3-556 (1	YES	ine

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

			U.\$. F	PATENT DOCUMENTS				
EXAMINER WITHAL	Γ	DOCUMENT NUMBER	DATE	NAME	CL	ASS S	SUBCLASS	FILING DATE
0	5AA	5,849,918	12/15/98	Esser et al.				
1/_	- 5AB	5,885,983	3/23/99	Biller et al.				
	5AC	5,962,440	10/5/99	Sulsky				
/	5AD	6,017,926	1/25/00	Askew et al.				
	5AE	6,043,265	3/28/00	Murugesan et al.				
	5AF	6,107,329	8/22/00	Hoover et al.	-			
	AG							
	АН							
	Al							************
	AJ						*******	
	AK							
	AL							
		DOCUMENT NUMBER	DATE	N PATENT DOCUMENTS OFFICE	CLASS	SUBCLA	ASS TRA	NSLATIO NO
	5AM	WO 97/43268	11/20/97	PCT				
	5AN	WO 99/00353	1/7/99	PCT				1
<i>C</i>	5AO	WO 99/26659	6/3/99	PCT				10
	5AP	WO 99/38501	8/5/99	PCT			- I	
r -								
	5AQ	WQ 99/46272	9/16/99	PCT				10
	 	WQ 99/46272	1		nt pages, E	itc.)		
	 	WO 99/46272 OTHER DOC Bundgaard, H., Chapt	UMENTS (er 5: "Desig	PCT	A Textbo	ok of Dr		and
	5AQ	WO 99/46272 OTHER DOC Bundgaard, H., Chapt Development, Harwoo (1991)	UMENTS (er 5: "Designed Academic	PCT Including Author, Title, Date, Pertiner In and Application of Prodrugs",	A Textbo	ook of Dr	eds., pp. 1	and 13-191
	5AQ 5AR	OTHER DOC Bundgaard, H., Chapt Development, Harwoo (1991) Bundgaard, H., ed., D contents) Caprathe, B.W. et al.,	UMENTS (er 5: "Designed Academic esign of Pro "Dopamine	PCT Including Author, Title, Date, Pertiner In and Application of Prodrugs", Publishers, publ., Krogsgaard-L	A Textbo arsen, P ers B.V., tial Antip	publ. (19	985) (table s. 3. 6-Pi	and 13-191
EXAMI	5AR- 5AS	OTHER DOC Bundgaard, H., Chapt Development, Harwoo (1991) Bundgaard, H., ed., D contents) Caprathe, B.W. et al., 4,5,5a,6,7,8-hexahydi	UMENTS (er 5: "Designed Academic esign of Pro "Dopamine	PCT Including Author, Title, Date, Pertiner In and Application of Prodrugs", Publishers, publ., Krogsgaard-L drugs, Elsevier Science Publisher Autoreceptor Agonists as Poten	A Textbo arsen, P ers B.V., tial Antip	publ. (19	985) (table s. 3. 6-Pi	and 13-191 of

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRAN YES	SLATION NO
Z	6AA	WO 99/61431	12/2/99	PCT				
<u></u>	6AB	WO 99/67278	12/29/99	PCT	-			
1	6AC	WO 99/67279	12/29/99	PCT	-		-0	
V	6AD	WO 00/01389	1/13/00	PCT				
<u></u>	6AE	WO 00/59506	10/12/00	PCT				
1	6AF	WO 01/00586	1/4/01	PCT				
U	6AG	WO 01/21602	3/29/01	PCT				
- Y	GAH	WO 01/27128	4/19/01	PCT				
	Al							
	AJ							
	AK							
	AL							
	AM							
	AN							
	AO							
	AP							
	AQ							
*****	AR							
	AS			•				
	AT							
	AU							
***************************************	AV		·					
	AW							
	AX							
	AY							
EXAM	AZ	/		DATE CONSIDERED		5-		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

Capson, T.L., "Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates Squalene Biosynthesis", dissertation, Department of Medicinal Chemistry, University of Utah, priv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (June 1987) Carling, R.W. et al., "3-Nitro-3,4-dihydro-2(1 <i>H</i>)-quinolines. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (<i>RS</i>)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors", J. Med. Chem., Vol. 36, No. 22, pp. 3397-3408 (1993) Casimir, J.R. et al., "Efficient Synthesis of (S)-4-Phthalimido-1,3,4,5-tetrahydro-8-(2,6-dichlorobenzyloxy)-3-oxo-2 <i>H</i> -2-benzazepin-2-acetic Acid (Pht-Hba(2,6-Cl ₂ -Bn)-Gly-OH)", J. Org Chem. Vol. 65, No. 20, pp. 6487-6492 (2000) Corey, E.J. et al., "Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Studies of Terpenoid Pyrophosphates to Studies of Studies of Terpenoid Pyrophosphates to Studies of Terpenoid Pyroph	o.
Carling, R.W. et al., "3-Nitro-3,4-dihydro-2(1 <i>H</i>)-quinolines. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (<i>RS</i>)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors", J. Med. Chem., Vol. 36, No. 22, pp. 3397-3408 (1993) Casimir, J.R. et al., "Efficient Synthesis of (<i>S</i>)-4-Phthalimido-1,3,4,5-tetrahydro-8-(2,6-dichlorobenzyloxy)-3-oxo-2 <i>H</i> -2-benzazepin-2-acetic Acid (Pht-Hba(2,6-Cl ₂ -Bn)-Gly-OH)", J. Org Chem. Vol. 65, No. 20, pp. 6487-6492 (2000)	
7AC dichlorobenzyloxy)-3-oxo-2 <i>H</i> -2-benzazepin-2-acetic Acid (Pht-Hba(2,6-Cl ₂ -Bn)-Gly-OH)", J. Org Chem. Vol. 65, No. 20, pp. 6487-6492 (2000)	1.
Corey, E.J. et al., "Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of	
7AD Multistep Biosynthesis. Demonstration That 'Presqualene Pyrophosphate' Is an Essential Intermediate on the Path to Squalene", J. Am. Chem. Soc., Vol. 98, No. 5, pp. 1291-1293 (1976)	5)
Cornicelli, J.A. et al., "15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vasc Disease", Current Pharmaceutical Design, Vol. 5, No. 1, pp. 11-20 (1999)	Jlar
Davis, A.L. et al., "Preparation and Antimicrobial Properties of the D and L Forms of 3-Amino-3, dihydro-1-hydroxycarbostyril", Journal of Medicinal Chemistry, Vol. 15, No. 3, pp. 325-327 (197	
Davis, A.L. et al., "Synthesis of the 3-Methyl and 4-Methyl Derivatives of 3-Amino-3,4-dihydro-1 hydroxycarbostyril and Related Compounds", J. Heterocyclic Chem., Vol. 17, pp. 1405-1408 (1	
Davis, A.L. et al., "The Syntheses and Biological Activities of o-Aminophenylalanine and Relate Compounds", Archives of Biochemistry and Biophysics, Vol. 102, pp. 48-51 (1963)	đ
DeVita, R.J. et al., "Heterocyclic Analogs of the Benzolactam Nucleus of the Non-Peptidic Grov Hormone Secretagogue L-692,429", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 12, 1281-1286 (1995)	
TAJ El-Subbagh, H.I. et al., "Synthesis and Antitumor Activity of Some New Substituted Quinolin-4-one Analogs", Arch. Pharm. Pharm. Med. Chem., Vol. 322, pp. 19-24 (1999)	ne
Epsztajn, J. et al., "Applications of Organolithium and Related Reagents in Synthesis. Part 3. 7AK General Study of the Reaction of Lithium Alkyls with Pyridine Ketones", J. Chem. Soc. Perkin Trans. I, pp. 213-219 (1985)	1
Ferraris, D. et al., "Catalytic, Enantioselective Alkylation of α-Imino Esters: The Synthesis of Nonnatural α-Amino Acid Derivatives", J. Am. Chem. Soc., Vol. 124, No. 1, pp. 67-77 (2002)	
Flynn, G.A. et al., "An Acyliminium Ion Route to <u>Cis</u> and <u>Trans</u> "Anti" Phe-Gly Dipeptide Mimeting Bioorganic & Medicinal Chemistry Letters, Vol. 1, No. 6, pp. 309-312 (1991)	s",
Ford, E.S. et al., "Prevalence of the Metabolic Syndrome Among US Adults", J. Am. Med. Asso 7AN Vol. 287, No. 3, pp. 356-359 (2002)	C.,
EXAMINER DATE CONSIDERED	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	844	Fu, Y. et al., "Sterically Hindered $C^{\alpha,\alpha}$ -Disubstituted α -Amino Acids: Synthesis from α -Nitroacetate and Incorporation into Peptides", J. Org. Chem., Vol. 66, No. 21, pp. 7118-7124 (2001)
<i>y</i>	8AB	Fujita, M. et al., "A Novel, Convenient Synthesis of 2-Aryl-3-oxo-3,4-dihydro-2 <i>H</i> -1,4-benzothiazines", Synthesis, pp. 599-604 (1988)
[8AC	Ghiselli, G., "The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein", Cardiovascular Drug Reviews, Vol. 16, No. 1, pp. 16-30 (1998)
<i></i>	8AD	Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons, Inc., publ., pp. ix-x (table of contents) (1991)
	8AE	Hamann, B.C. et al., "Sterically Hindered Chelating Alkyl Phosphines Provide Large Rate Accelerations in Palladium-Catalyzed Amination of Aryl Iodides, Bromides, and Chlorides, and the First Amination of Aryl Tosylates", J. Am. Chem. Soc., Vol. 120, No. 29, pp. 7369-7370 (1998)
[8AF	Hara, S., "Ileal Na*/bile acid cotransporter inhibitors", Drugs of the Future, Vol. 24, No. 4, pp. 425-430 (1999)
6	8AG	Hoover, D.J. et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase", J. Med. Chem., Vol. 41, No. 16, pp. 2934-2938 (1998)
	8AH	Huang, Y. et al., "The Improved Preparation of 7,8-dihydro-quinoline-5(6H)-one and 6,7-dihydro-5H-1-pyridin-5-one", Synthetic Communications, Vol. 28, No. 7, pp. 1197-1200 (1998)
	8AI	Itoh, K. et al., "Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,5-Benzothiazepine and 1,5-Benzoxazepine Derivatives", Chem. Pharm. Bull., Vol. 34, No. 3, pp. 1128-1147 (1986)
/	8AJ	Jackson, R.F.W. et al., "Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry: NMR Studies of Amino Acid-Derived Organozinc Reagents", J. Org. Chem., Vol. 63, No. 22, pp. 7875-7884 (1998)
7	8AK	Jössang-Yanagida, A. et al., "Tetrahydropyridoazepines and Tetrahydropyridoazepinones from the Corresponding Dihydroquinolines", J. Heterocyclic Chem., Vol. 15, pp. 249-251 (1978)
4	8AL	Kikelj, D. et al., "A Convenient Synthesis of 3,4-Dihydro-2-methyl-3-oxo-2 <i>H</i> -1,4-benzoxazine-2-carboxylic Acids and 3,4-Dihydro-2-methyl-3-oxo-2 <i>H</i> -pyrido[3,2- <i>b</i>]-1,4-oxazine-2-carboxylic Acid", J. Heterocyclic Chem., Vol. 30, pp. 597-602 (1993)
4	8AM	Kluge, M. et al., "Syntheses for 2-Amino and 2-Mercapto-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i>)-one and 2 <i>H</i> -1,4-Benzothiazin-3(4 <i>H</i>)-one as Aza and Thio Analogues of the Natural Product <i>Blepharigenin</i> ", J. Heterocyclic Chem., Vol. 33, pp. 1623-1626 (1996)
6	8AN	Krause, B.R. et al., Chapter 6: "ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals", Inflammation: Mediators Pathways, CRC Press Inc., publ., Ruffolo, Jr., R.R. et al., eds., pp. 173-198 (1995)
EXAMINE	R	DATE CONSIDERED
	/	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

9AA	Lardenois, P. et al., "A Convenient Synthesis of 7,8-dihydroisoquinolin-5(6H)-one", Synthetic Communications, Vol. 26, No. 12, pp. 2305-2308 (1996)
9AB	Larock, R.C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., publ., pp. xiii-xxviii (table of contents) (1989)
9AC	Lowe, III, J.A. et al., "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists", J. Med. Chem., Vol. 37, No. 22, pp. 3789-3811 (1994)
9AD	Martin, W.H. et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo", Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1776-1781 (1998)
9AE	McCord, T.J. et al., "The Synthesis, Configuration, and Conformation of <i>cis</i> - and <i>trans</i> -3-Amino-3,4-dihydro-1-hydroxy-4-methylcarbostyrils and Other Configurationally Related Compounds", J. Heterocyclic Chem., Vol. 18, pp. 1035-1039 (1981)
9AF	Morton, G.C. et al., "Novel solid-phase synthesis of 1,5-benzothiazepine-4-one derivatives", Tetrahedron Letters, Vol. 41, pp. 3029-3033 (2000)
9AG	Murakami, K. et al., "A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator- Activated Receptor-α (PPAR-α) and PPAR-γ: Effect of PPAR-α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes, Vol. 47, pp. 1841-1847 (1998)
9AH	Murakami, Y. et al., "1,3-Disubstituted Benzazepines as Novel, Potent, Selective Neuropeptide Y Y1 Receptor Antagonists", J. Med. Chem., Vol. 42, No. 14, pp. 2621-2632 (1999)
9AI	Neumeyer, J.L. et al., "Aporphines. 21. Dopaminergic Activity of Aporphine and Benzylisoquinoline Derivatives. Synthesis of 8-Hydroxyaporphines and 1-(Hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines", Journal of Medicinal Chemistry, Vol. 20, No. 2, pp. 190-196 (1977)
9AJ	Nicolosi, R.J. et al., "The ACAT Inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Atherosclerosis, Vol. 137, pp. 77-85 (1998)
9AK	Ortiz de Montellano, P.R. et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", Journal of Medicinal Chemistry, Vol. 20, No. 2, pp. 243-249 (1977)
9AL	Parsons, W.H. et al., "Benzolactams. A New Class of Converting Enzyme Inhibitors", Biochemical and Biophysical Research Communications, Vol. 117, No. 1, pp. 108-113 (1983)
9AM	Rabi-Barakay, A. et al., "Intramolecular Amidoalkylation of Aromatics III. Synthesis of Conformationally Restricted Bridged Peptide Analogues of Phe-Gly", Tetrahedron, Vol. 50, No. 36, pp. 10771-10782 (1994)
9AN	Robl, J.A. et al., "Dual Metalloprotease Inhibitors. I. Constrained Peptidomimetics of Mercaptoacy Dipeptides", Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 15, pp. 1789-1794 (1994)
R	DATE CONSIDERED // // XX
	9AB 9AC 9AD 9AE 9AF 9AG 9AH 9AI 9AJ 9AK

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

10AA	Active Inhibitor of Cholesterol Absorption", J. Med. Chem., Vol. 41, No. 6, pp. 973-980 (1998)
10AB	Saari, W.S. et al., "Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin-2(1 <i>H</i>)-one", J. Med. Chem., Vol. 35, No. 21, pp. 3792-3802 (1992)
10AC	Salisbury, B.G. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461", Atherosclerosis, Vol. 115, pp. 45-63 (1995)
10AD	Schoen, W.R. et al., "A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692,429)", Vol. 37, No. 7, pp. 897-906 (1994)
10AE	Pharmacology, Vol. 120, pp. 1199-1206 (1997)
10AF	Sicker, D. et al., "A Convenient Synthesis of Heterocyclic N-Hydroxylactams", Synthesis, pp. 331-333 (1985)
10AG	Sicker, D. et al., "Syntheses for 2-Hydroxy-2 <i>H</i> -1,4-benzothiazin-3(4 <i>H</i>)-one Derivatives as Thio Analogues of Natural Hemiacetals", J. Heterocyclic Chem., Vol. 31, pp. 809-812 (1994)
10AH	Slade, J. et al., "Angiotensin Converting Enzyme Inhibitors: 1,5-Benzothiazepine Derivatives", J. Med. Chem., Vol. 28, No. 10, pp. 1517-1521 (1985)
10AI	Sliskovic, D.R. et al., "ACAT Inhibitors: Potential Anti-atherosclerotic Agents", Current Medicinal Chemistry, Vol. 1, No. 3, pp. 204-225 (1994)
10AJ	Smith, C. et al., "RP 73163: A Bioavailable Alkylsulphinyl-Diphenylimidazole ACAT Inhibitor", Bioorganic & Medicinal Chemistry Letters", Vol. 6, No. 1, pp. 47-50 (1996)
10AK	Activity, etc.", Chemtracts-Organic Chemistry, Vol. 8, pp. 359-362 (1995)
10AL	Tamura, S.Y. et al., "Novel Benzo-Fused Lactam Scaffolds as Factor Xa Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 9, pp. 2573-2578 (1999)
10AM	Tietze, L.F. et al., "First Synthesis and Structural Determination of Blepharin and 1'-Epiblepharin", Synthesis, pp. 1118-1120 (1991)
(10AN	Turconi, M. et al., "Synthesis, Absolute Configuration, Conformational Analysis and Binding Affinity Properties of Enantiomeric Forms of DAU 5750, a Novel M1-M3 Muscarinic Receptor Antagonist", Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 12, pp. 1375-1383 (1994)
EXAMINER	DATE CONSIDERED /

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0093 NP APPLICATION NO. 10/712,823 APPLICANT SHER ET AL. FILING DATE NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		OTTER DOODNEER TO (Michael Addition, Title, Date, Fertilient pages, Etc.)
<i></i>	11AA	van Niel, M.B. et al., "CCK _B Selective Receptor Ligands: Novel 1,3,5-trisubstituted benzazepin-2-ones", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 13, pp. 1421-1426 (1995)
	1TAB	Watthey, J.W.H. et al., "Synthesis and Biological Properties of (Carboxyalkyl)amino-Substituted Bicyclic Lactam Inhibitors of Angiotensin Converting Enzyme", J. Med. Chem., Vol. 28, No. 10, pp. 1511-1516 (1985)
	11AC	Wermuth, C.G. et al., Chapter 31: "Designing Prodrugs and Bioprecursors I: Carrier Prodrugs", The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996)
	11AD	Worley, J.W. et al., "2-Dialkylphosphonyl- and 2-Alkylidene-3,4-dihydro-3-oxo-2 <i>H</i> -1,4-benzothiazines", J. Org. Chem., Vol. 40, No. 12, pp. 1731-1734 (1975)
	11AE	Yamada, M. et al., "A Potent Dipeptide Inhibitor of Dipeptidyl Peptidase IV", Bioorganic & Medicina Chemistry Letters, Vol. 8, pp. 1537-1540 (1998)
	AF	
	AG	
	АН	
	AI	
	AJ	
	AK	
	AL	
, , , , , , , , , , , , , , , , , , , 	АМ	
	AN .	
EXAMI	NER	DATE CONSIDERED